North Texas Kidney Disease Associates

Our Patient Portal can be accessed here.


Message to our patients regarding COVID-19

As we continue to navigate the changing response to the COVID19 pandemic, we plan to slowly open our offices for limited in-office appointments to ensure that we can continue to keep our patients and staff safe.

Patients with upcoming appointments will be contacted by our office to confirm an in-office appointment or a Telemedicine visit with your physicians. 

We are in unprecedented times and we want you to know we are here for you. There is nothing more important to us than the health of our patients, your families, and the community. 

From your physicians and staff at North Texas Kidney Disease Associates  


RevUp offers you a personal Health Coach that will help you successfully achieve your goals by managing your day-to-day health, while keeping your health care team up to date on how you are doing.

North Texas Kidney Disease Associates (NTKDA) offices of Dallas, Denton, Flower Mound, Frisco, Keller, Lewisville, North Richland Hills, and two in Plano, have received recognition as a Patient-Centered Specialty Practice (PCSP) by The National Committee for Quality Assurance (NCQA).
Earning NCQA Recognition shows that NTKDA has undergone a rigorous review of its capabilities and is committed to communication, coordination and providing access to care.  Recognition signals to primary care practices that North Texas Kidney Disease Associates is ready to be an effective partner in caring for patients they have in common.

Patient Education Classes:


Our Mission:

Our mission is to be the premier provider of comprehensive health care services for patients with kidney disease. We will deliver health care in a professional, compassionate and individualized manner designed to promote mutual respect and foster strong doctor-patient relationships.

Medical Tidbits:

June 15th
MedPage Today (6/14, Brown) reports that “the FDA is strengthening a warning on the labels of two diabetes drugs to reflect risk of acute kidney injuries.” The “new labels for the two sodium-glucose transport 2 (SGLT-2) drugs &ndash…